Formycon Reports the MHRA’s Approval of FYB203 (Biosimilar, Eylea) as Ahzantive
Shots:
- Following the EC approval, Formycon & Klinge Biopharma have reported the UK MHRA’s approval of FYB203, biosimilar of Eylea (aflibercept), under the brand name: Ahzantive
- The biosimilar is intended to treat Age-Related Neovascular (wet) Macular Degeneration (nAMD) and other serious retinal diseases incl. Diabetic Macular Edema (DME), visual impairment due to Myopic Choroidal Neovascularization (CNV) & Macular Edema following Retinal Vein Occlusion (RVO)
- Furthermore, Formycon & Teva Pharmaceuticals have partnered for the semi-exclusive commercialization of FYB203 in major parts of EU, including the UK & Israel. Formycon had concluded a product supply agreement with Teva, which is already marketing Formycon’s FYB201 ranibizumab biosimilar (Ongavia) in UK and will leverage its existing ophthalmology infrastructure and distribution channels
Ref: Formycon | Image: Formycon
Related News:- Formycon Reports the EC’s Approval of FYB203 (Biosimilar, Eylea) Under the Brand Names Ahzantive and Baiama
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
